Press Releases

Caribou Biosciences Appoints Timothy F. Herpin, Ph.D. as Chief Business Officer

May 3, 2018

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading genome editing company, announced today that it has appointed Timothy F. Herpin, Ph.D. as its first Chief Business Officer. In this role, Tim will lead the company's efforts in the areas of strategic partnerships, licensing agreements, and other value creation opportunities.

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing

July 25, 2017

Appeal seeks reversal of Patent Trial and Appeal Board decision terminating interference without determining priority of inventorship of CRISPR/Cas9 gene editing Brief asserts that the Board failed to properly apply controlling U.S. Supreme Court and Federal Circuit precedents, and ignored evidence of multiple groups readily applying CRISPR/Cas9 gene editing to eukaryotic cells following teachings of Charpentier-Doudna team

Caribou Biosciences Appoints Steven B. Kanner, Ph.D. as Chief Scientific Officer

July 6, 2017

BERKELEY, CA– July 6, 2017 – Caribou Biosciences, Inc., a leading genome engineering company, announced today that Steven B. Kanner, Ph.D. has joined the Company as Chief Scientific Officer. Dr. Kanner brings more than 25 years of experience in drug discovery and development and will lead Caribou’s research and development of new applications for its gene editing technology.

Caribou Biosciences Announces Grant of a Key CRISPR-Cas9 Genome Editing Patent in Europe

May 10, 2017

Patent covers foundational CRISPR-Cas9 inventions for which Caribou holds an exclusive license from the University of California and the University of Vienna Claims cover CRISPR-Cas9 compositions for use in any non-cellular and cellular setting, including eukaryotic cells

Caribou Biosciences Announces Grant of a Key CRISPR-Cas9 Patent in the U.S.

May 2, 2017

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading company in CRISPR-Cas genome engineering, today announced that the United States Patent and Trademark Office (USPTO) has granted Vilnius University a CRISPR-Cas9 genome editing patent. Caribou has rights to this intellectual property in multiple fields of use, including exclusive access in the research tools field. Caribou gained these rights as part of its worldwide cross-license agreement with DuPont Company, to which Vilnius University exclusively licensed this intellectual property.